Cannabinoids in Metabolic Syndrome and Cardiac Fibrosis

Navarrete, Carmen; García‐Martín, Adela; DeMesa, Jim; Muñóz, Eduardo

doi:10.1007/s11906-020-01112-7

Cited by 6 publications

(7 citation statements)

References 98 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In relation to eating behavior, emerging evidence points to an important role of cannabinoids in regulating appetite, and consequently food intake. Additionally, cannabinoids are also an important player in the reward circuitries [ 13 – 16 ]. Thus, we found it timely to conduct a review in order to better clarify the potential impact of CBD on appetite and body weight in humans.…”

Section: Introductionmentioning

confidence: 99%

Effects of Cannabidiol on Appetite and Body Weight: A Systematic Review

Pinto

Martel

2022

Clin Drug Investig

View full text Add to dashboard Cite

Background and Objective Cannabidiol, one of the main components of the Cannabis sativa plant, is a non-psychotropic cannabinoid that has recently drawn the attention of researchers and clinicians for its potential therapeutic applications. In this systematic review, we aim to describe the possible effects of cannabidiol in appetite and body weight. Methods Both authors independently ran a thorough search in both PubMed and Cochrane databases up to 31 July, 2022 and included every peer-reviewed, original randomized controlled clinical trial that reported data on either of the said outcomes. Risk of assessment bias was performed with Cochrane’s risk of bias tool and results were summarized in tables. Results A total of 11 trials were included in this review. Of these, the majority reported on cannabidiol reducing appetite and/or body weight whilst some have found no significant changes and one trial described an increase in appetite. Conclusions This systematic review suggests that cannabidiol has an anorexigenic effect, correlated with a decrease in body weight. However, most of the studies included in the present review raised some concerns in terms of risk of bias. We believe further research is needed in order to clarify potential mechanisms involved in the effect of cannabidiol on feeding/appetite. Supplementary Information The online version contains supplementary material available at 10.1007/s40261-022-01205-y.

show abstract

Section: Introductionmentioning

confidence: 99%

Effects of Cannabidiol on Appetite and Body Weight: A Systematic Review

Pinto

Martel

2022

Clin Drug Investig

View full text Add to dashboard Cite

show abstract

“…Cannabis seems to have also deleterious long-term effects [139], thus dooming both adolescents and adults to the use of antipsychotics with related cardiometabolic liabilities due to adverse drug effects [140]. However, the ambiguity of cannabis makes it potentially both harmful to the heart [141] and beneficial in cardiovascular diseases [142]. The drug may have clinical applications for the treatment of autism spectrum disorder [143], and CBD showed antipsychotic potential.…”

Section: Discussionmentioning

confidence: 99%

Endocannabinoid Degradation Enzyme Inhibitors as Potential Antipsychotics: A Medicinal Chemistry Perspective

et al. 2023

View full text Add to dashboard Cite

The endocannabinoid system (ECS) plays a very important role in numerous physiological and pharmacological processes, such as those related to the central nervous system (CNS), including learning, memory, emotional processing, as well pain control, inflammatory and immune response, and as a biomarker in certain psychiatric disorders. Unfortunately, the half-life of the natural ligands responsible for these effects is very short. This perspective describes the potential role of the inhibitors of the enzymes fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MGL), which are mainly responsible for the degradation of endogenous ligands in psychic disorders and related pathologies. The examination was carried out considering both the impact that the classical exogenous ligands such as Δ9-tetrahydrocannabinol (THC) and (−)-trans-cannabidiol (CBD) have on the ECS and through an analysis focused on the possibility of predicting the potential toxicity of the inhibitors before they are subjected to clinical studies. In particular, cardiotoxicity (hERG liability), probably the worst early adverse reaction studied during clinical studies focused on acute toxicity, was predicted, and some of the most used and robust metrics available were considered to select which of the analyzed compounds could be repositioned as possible oral antipsychotics.

show abstract

“…In the 1960s, the principal ingredients of the cannabis plant, cannabidiol (CBD), and Δ9-tetrahydrocannabinol (Δ9-THC) were isolated. 3 Subsequent research led to the identification of the endocannabinoid system (ECS) as the main regulator of body homeostasis. The eCBs, receptors, and enzymes are part of ECS, which are found in the central nervous system (CNS) and peripheral tissues and are involved in maintaining homeostasis of metabolism, the immune system, and the cardiovascular system.…”

Section: Endocannabinoids and Endocannabinoid Receptorsmentioning

confidence: 99%

“…The synthesis and catabolism of the eCBs are modulated by complex enzymatic pathways. 5 The activity of eCB ligands is regulated by the enzymes fatty acid amide hydrolase (FAAH) and monoacyl glycol lipase (MAGL), 3 which hydrolysis AEA to arachidonic acid and 2-AG to ethanolamine or glycerol, respectively. 5 Generally, there are two well-characterized cannabinoid receptors (CBR) with distinct physiological properties.…”

Section: Endocannabinoids and Endocannabinoid Receptorsmentioning

confidence: 99%

See 1 more Smart Citation

Cannabinoids in neuroinflammatory disorders: Focusing on multiple sclerosis, Parkinsons, and Alzheimers diseases

et al. 2023

View full text Add to dashboard Cite

The medicinal properties of cannabis and cannabinoid-derivative are entirely investigated and known. In addition, the identification of psychotropic plant cannabinoids has led to more studies regarding the cannabinoid system and its therapeutic features in the treatment and management of clinical symptoms of neuroinflammatory disorders, such as multiple sclerosis (MS), Parkinsons disease (PD), and Alzheimers disease (AD). In fact, cannabinoid agonists are able to control and regulate inflammatory responses. In contrast to the cannabinoid receptor type 1 (CB1) and its unwanted adverse effects, the cannabinoid receptor type 2 (CB2) and its ligands hold promise for new and effective therapeutic approaches. So far, some successes have been achieved in this field. This review will discuss an outline of the endocannabinoid system's involvement in neuroinflammatory disorders. Moreover, the pharmacological efficacy of different natural and synthetic preparations of phytocannabinoids acting on cannabinoid receptors, particularly in MS, PD, and AD, will be updated. Also, the reasons for targeting CB2 for neurodegeneration will be explained.

show abstract

Cannabinoids in Metabolic Syndrome and Cardiac Fibrosis

Cited by 6 publications

References 98 publications

Effects of Cannabidiol on Appetite and Body Weight: A Systematic Review

Effects of Cannabidiol on Appetite and Body Weight: A Systematic Review

Endocannabinoid Degradation Enzyme Inhibitors as Potential Antipsychotics: A Medicinal Chemistry Perspective

Cannabinoids in neuroinflammatory disorders: Focusing on multiple sclerosis, Parkinsons, and Alzheimers diseases

Contact Info

Product

Resources

About